

KIAA1107 (G-20): sc-247287

BACKGROUND

KIAA1107 is a 1,409 amino acid protein that is phosphorylated at serine 891 upon DNA damage, potentially by ATM or ATR. KIAA1107 exists as 2 alternatively spliced isoforms and is encoded by a gene that maps to human chromosome 1. Chromosome 1 is the largest chromosome, which spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8% of the human genome. Chromosome 1 houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson's disease, Gaucher disease, schizophrenia and Usher syndrome. Aberrations in chromosome 1 are found in a variety of cancers, including head and neck cancer, malignant melanoma and multiple myeloma.

REFERENCES

1. Eudy, J.D., et al. 1998. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type II α . *Science* 280: 1753-1757.
2. Kikuno, R., et al. 1999. Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins *in vitro*. *DNA Res.* 6: 197-205.
3. Tayebi, N., et al. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. *Mol. Genet. Metab.* 73: 313-321.
4. Plasilova, M., et al. 2004. Exclusion of an extracolonic disease modifier locus on chromosome 1p33-36 in a large Swiss familial adenomatous polyposis kindred. *Eur. J. Hum. Genet.* 12: 365-371.
5. Matsuoaka, S., et al. 2007. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* 316: 1160-1166.
6. Betarbet, R., et al. 2008. Fas-associated factor 1 and Parkinson's disease. *Neurobiol. Dis.* 31: 309-315.
7. Holliday, E.G., et al. 2009. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. *Am. J. Psychiatry* 166: 206-215.
8. Balcárková, J., et al. 2009. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma. *Cancer Genet. Cytogenet.* 192: 68-72.
9. Yokoi, T., et al. 2009. Analysis of the vitreous membrane in a case of type 1 Stickler syndrome. *Graefes. Arch. Clin. Exp. Ophthalmol.* 247: 715-718.

CHROMOSOMAL LOCATION

Genetic locus: KIAA1107 (human) mapping to 1p22.1; A830010M20Rik (mouse) mapping to 5 E5.

SOURCE

KIAA1107 (G-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of KIAA1107 of human origin.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-247287 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

KIAA1107 (G-20) is recommended for detection of KIAA1107 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

KIAA1107 (G-20) is also recommended for detection of KIAA1107 in additional species, including equine, canine and avian.

Molecular Weight of KIAA1107 isoforms: 156/139 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.